X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs CADILA HEALTHCARE - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES CADILA HEALTHCARE DIVIS LABORATORIES/
CADILA HEALTHCARE
 
P/E (TTM) x 18.5 35.8 51.6% View Chart
P/BV x 4.0 9.2 43.4% View Chart
Dividend Yield % 1.5 0.7 233.2%  

Financials

 DIVIS LABORATORIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
CADILA HEALTHCARE
Mar-16
DIVIS LABORATORIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs2,484454 546.6%   
Low Rs918305 301.5%   
Sales per share (Unadj.) Rs142.396.1 148.0%  
Earnings per share (Unadj.) Rs41.914.9 281.6%  
Cash flow per share (Unadj.) Rs46.317.8 259.9%  
Dividends per share (Unadj.) Rs10.003.20 312.5%  
Dividend yield (eoy) %0.60.8 69.7%  
Book value per share (Unadj.) Rs161.552.3 309.0%  
Shares outstanding (eoy) m265.471,023.74 25.9%   
Bonus/Rights/Conversions -FV5:1-  
Price / Sales ratio x12.03.9 302.8%   
Avg P/E ratio x40.625.5 159.2%  
P/CF ratio (eoy) x36.721.3 172.4%  
Price / Book Value ratio x10.57.3 145.1%  
Dividend payout %23.921.5 111.0%   
Avg Mkt Cap Rs m451,525388,458 116.2%   
No. of employees `0003.715.4 24.0%   
Total wages/salary Rs m3,64913,317 27.4%   
Avg. sales/employee Rs Th10,184.46,371.1 159.9%   
Avg. wages/employee Rs Th984.1862.4 114.1%   
Avg. net profit/employee Rs Th2,998.5986.1 304.1%   
INCOME DATA
Net Sales Rs m37,76498,376 38.4%  
Other income Rs m848941 90.2%   
Total revenues Rs m38,61299,317 38.9%   
Gross profit Rs m14,13823,829 59.3%  
Depreciation Rs m1,1823,022 39.1%   
Interest Rs m23486 4.8%   
Profit before tax Rs m13,78121,262 64.8%   
Minority Interest Rs m0-300 0.0%   
Prior Period Items Rs m05 0.0%   
Extraordinary Inc (Exp) Rs m0-25 0.0%   
Tax Rs m2,6625,716 46.6%   
Profit after tax Rs m11,11915,226 73.0%  
Gross profit margin %37.424.2 154.6%  
Effective tax rate %19.326.9 71.9%   
Net profit margin %29.415.5 190.2%  
BALANCE SHEET DATA
Current assets Rs m30,94744,376 69.7%   
Current liabilities Rs m5,19534,071 15.2%   
Net working cap to sales %68.210.5 651.0%  
Current ratio x6.01.3 457.4%  
Inventory Days Days11754 216.8%  
Debtors Days Days8562 136.6%  
Net fixed assets Rs m17,02747,896 35.5%   
Share capital Rs m5311,024 51.8%   
"Free" reserves Rs m42,34148,746 86.9%   
Net worth Rs m42,87753,519 80.1%   
Long term debt Rs m58,964 0.1%   
Total assets Rs m49,684100,163 49.6%  
Interest coverage x595.044.7 1,329.6%   
Debt to equity ratio x00.2 0.1%  
Sales to assets ratio x0.81.0 77.4%   
Return on assets %22.415.7 143.0%  
Return on equity %25.928.4 91.1%  
Return on capital %32.234.3 93.9%  
Exports to sales %85.345.3 188.3%   
Imports to sales %22.95.9 386.2%   
Exports (fob) Rs m32,19844,537 72.3%   
Imports (cif) Rs m8,6545,838 148.2%   
Fx inflow Rs m32,27044,881 71.9%   
Fx outflow Rs m8,7759,069 96.8%   
Net fx Rs m23,49635,812 65.6%   
CASH FLOW
From Operations Rs m10,37919,938 52.1%  
From Investments Rs m-4,135-9,039 45.7%  
From Financial Activity Rs m-6,241-9,527 65.5%  
Net Cashflow Rs m31,372 0.2%  

Share Holding

Indian Promoters % 52.0 74.8 69.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 8.3 142.2%  
FIIs % 19.0 5.9 322.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 11.0 156.4%  
Shareholders   31,796 44,069 72.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  SUVEN LIFE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 17, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - VENUS REMEDIES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS